ReviewFrontiers in oncology2026
Diversity within ovarian cancer subtypes and their tumor microenvironment.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the deadliest gynecologic cancer in individuals assigned female at birth. Patients diagnosed with ovarian cancer experience poor survival rates due to frequent late-stage diagnosis and aggressive metastases. Ovarian cancer is often diagnosed at stages III or IV, where survival rates decline substantially. Ovarian cancer comprises several subtypes, each with distinct biological characteristics, clinical behaviors, and treatment responses, thereby complicating the identification of effective therapeutic targets. This review focuses primarily on the most prevalent subtype, high-grade serous carcinoma (HGSC) while also considering less common subtypes such as low-grade serous carcinoma, endometrioid carcinoma, clear cell and mucinous carcinomas. The tumor microenvironment (TME) plays a central role in tumor progression, metastasis, and immune evasion, thereby influencing therapeutic response and patient outcomes. Therefore, understanding the interactions between cancer cells and their microenvironment is essential for developing innovative therapeutic strategies. By identifying subtype-specific biomarkers and disease mechanisms, we can enhance diagnostic accuracy and develop tailored treatment approaches. A deeper understanding of ovarian cancer subtypes and their unique characteristics is vital for advancing patient care, driving innovations in early detection, and ultimately improving survival rates in this complex disease. This review emphasizes the potential for identifying novel biomarkers within the TME, which could facilitate earlier diagnosis and the development of targeted treatments for specific ovarian cancer subtypes, ultimately reducing mortality rates in this challenging cancer landscape.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.